Clinical trials: Liver Tumors
Liver Neoplasms, Adenoma
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
Medical records are reviewed to obtain information about the use of a MRI diagnostic imaging agent (contrast agent) called Primovist/Eovist in children older than 2 months and less than 18 years.
- Conditions
- Liver Neoplasms, Adenoma, Carcinoma, Liver Abscess
- Trial name
- NCT01043523
- Testing
- Gadoxetic Acid Disodium (Eovist, BAY86-4873)
- Where
- 9 sites in United States, Italy and 3 more
- Volunteers
- 52 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
A Study of Pexa-Vec (JX-594) Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously and intratumorally prior to standard sorafenib therapy.
- Trial name
- NCT01171651
- Testing
- JX-594, Sorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Jennerex Biotherapeutics
Carcinoma, Hepatocellular
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
The primary purpose of the study is to explore whether treatment with PF-03446962 and best supportive care is better than placebo plus best supportive care in prolonging survival of patients affected by recurrent liver cancer.
- Trial name
- NCT01911273
- Testing
- PF-03446962, Best Supportive Care
- Where
- 4 sites in United States, Japan
- Volunteers
- 3 people
- Sponsor
- Pfizer
Hepatic Carcinoma
Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy
To evaluate the efficacy and safety of Huaier Granule for prevention of disease progression of hepatocarcinoma after non-radical hepatectomy.
- Trial name
- NCT01760616
- Testing
- Huaier Granule
- Where
- China
- Volunteers
- 790 people
- Sponsor
- Qidong Gaitianli Medicines Co., Ltd
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Systemic Fungal Infections
Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
This multicenter observational cohort study proposes to establish the risks of short and long-term outcomes in users of parenteral micafungin and in users of other parenteral antifungal agents from 2005 through 2012 with…
- Trial name
- MYCOS (NCT01686607)
- Testing
- Parenteral micafungin application, Other parenteral antifungal drugs
- Where
- 6 sites in United States
- Volunteers
- 40,110 people
- Sponsor
- Astellas Pharma Europe B.V.
Carcinoma, Hepatocellular
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Nexavar for unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT01411436
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Japan
- Volunteers
- 1,637 people
- Sponsor
- Bayer
Liver Carcinoma
Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma
The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.
- Trial name
- NCT00791544
- Testing
- AVE1642, sorafenib, erlotinib
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Sanofi
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE)…
- Trial name
- NCT06600321
- Testing
- ALN-BCAT, Pembrolizumab
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 158 people
- Sponsor
- Alnylam Pharmaceuticals
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Liver Biopsy
Identification of Liver Tumours Using BIP - Biopsy System
This clinical device investigation is conducted by performing liver biopsies using the BIP - Biopsy Tool. The aim is to assess the feasibility of bioimpedance spectroscopy based biopsy tool guidance method and test how well BIP…
- Trial name
- NCT02620228
- Testing
- BIP Biopsy System
- Where
- Finland
- Volunteers
- 26 people
- Sponsor
- Injeq Ltd
Carcinoma, Hepatocellular
A Study of LY2157299 in Participants With Hepatocellular Carcinoma
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
- Trial name
- NCT01246986
- Testing
- LY2157299, Sorafenib, Ramucirumab
- Where
- 40 sites in United States, Australia and 5 more
- Volunteers
- 204 people
- Sponsor
- Eli Lilly and Company
Liver Metastasis, Pelvic Cancer
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
This multi-center photodynamic therapy study plans to treat patients with large tumors in any superficial location, sarcoma, tumors of oral/oro-pharyngeal cavity, tumors with extensive pelvic involvement, or liver metastasis.
- Conditions
- Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma
- Trial name
- NCT00028405
- Testing
- LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Light Sciences LLC
Carcinoma, Hepatocellular
Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety
The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety…
- Trial name
- SORINT (NCT01908322)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Neoplasms
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and…
- Trial name
- NCT02315066
- Testing
- PF-04518600, PF-04518600 plus PF-05082566
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 174 people
- Sponsor
- Pfizer
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China.
- Trial name
- NCT06712017
- Testing
- Yttrium-90 (Y-90) resin microspheres
- Where
- 6 sites in China
- Volunteers
- 100 people
- Sponsor
- GrandPharma (China) Co., Ltd.
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Neoplasm, Hepatocellular Carcinoma
Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)
The purpose of this study is to determine whether recombinant human arginase (PEG-BCT-100) is safe and effective in the treatment of advanced hepatocellular carcinoma (HCC).
- Trial name
- BCT-100-002 (NCT01092091)
- Testing
- Pegylated Recombinant Human Arginase I
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Bio-Cancer Treatment International Limited
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT03582618
- Testing
- Sorafenib, CVM-1118
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- TaiRx, Inc.